This invention is directed generally to compositions for animal consumption that comprise omega-3 and omega-6 polyunsaturated fatty acids in a specific weight ratio for reducing mitogen-activated-protein kinase (MAPK) activity, treating tissue hyperplasia and treating MAPK linked cancer. The compositions comprise at least 8% by weight fat, 50 to 75% by weight protein and less than 30% by weight carbohydrate, on a dry matter basis.